Cardiovascular morbidity associated with nonadherence to statin therapy

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1035-1043

  Blackburn, David F ^a   Dobson, Roy T ^a   Blackburn, James L ^a   Wilson, Thomas W ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adherence; Compliance; HMG CoA reductase inhibitors; Morbidity; Outcomes; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; WARFARIN;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT REFUSAL; UNSTABLE ANGINA PECTORIS;

ADULT; AGE FACTORS; AGED; ANGIOPLASTY, BALLOON; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CORONARY ARTERY BYPASS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; RECURRENCE; RISK FACTORS; SASKATCHEWAN; TREATMENT OUTCOME;

EID: 23244451173     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1035     Document Type: Article

References (25)

1. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
2. Sacks F, Pfeffer M, Moye L, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
4. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
5. Downs J, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-22.
6. Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomized trial. Lancet 2003;361:1149-58.
7. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy 2001;21:576-82.
9. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25.
10. Andrade S, Walker A, Gottleib L, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
11. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62.
12. Kiortsis D, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25:445-51.
13. Muhlestein J, Horne B, Bair T, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-61.
14. Benner J, Glynn R, Mogun H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
15. Jackevicius C, Mamdani M, Tu J. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
16. Downey W, Beck P, McNutt M, Stang M, Osei O, Nichol J. Health databases in Saskatchewan. In: Strom B, ed. Pharmacoepidemiology, 3rd edition. Chichester: Wiley, 2000:325-45.
17. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002;53:375-8.
18. Korf MV, Wagner E, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
19. Johnson J, Majumdar S, Simpson S, Toth E. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8.
20. Klungel O, Heckbert S, de Boer A, et al. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 2002;36:751-7.
21. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six-year follow-up study. Heart 2002;88:229-33.
22. Cannon CP, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
23. Saskatchewan Health Drug Plan and Extended Benefits Branch. Annual statistical report 2000-01. Government of Saskatchewan. Available from http://formulary.drugplan. health.gov.sk.ca/publications/2000- 2001%20Annual%20Report .pdf. Accessed February 2, 2005.
24. Rawson N, Malcom E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.
25. Petersen L, Wright S, Normand S, Daley J. Positive predictive value of acute myocardial infarction in an administrative database. J Gen Intern Med 1999;14:555-8.